112 related articles for article (PubMed ID: 3198661)
1. The effects of purified pertussis components and lipopolysaccharide on the results of the mouse weight gain test.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
J Biol Stand; 1988 Oct; 16(4):321-31. PubMed ID: 3198661
[TBL] [Abstract][Full Text] [Related]
2. The effects of purified components of Bordetella pertussis in the weight gain test for the toxicity testing of pertussis vaccines.
Redhead K; Seagroatt V
J Biol Stand; 1986 Jan; 14(1):57-65. PubMed ID: 2870067
[TBL] [Abstract][Full Text] [Related]
3. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
4. Quantification of pertussis toxin, filamentous haemagglutinin, 69 kDa outer membrane protein, agglutinogens 2 and 3 and lipopolysaccharide in the Danish whole-cell pertussis vaccine.
Ibsen PH; Petersen JW; Heron I
Vaccine; 1993; 11(3):318-22. PubMed ID: 8447160
[TBL] [Abstract][Full Text] [Related]
5. A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.
Tan LU; Fahim RE; Jackson G; Phillips K; Wah P; Alkema D; Zobrist G; Herbert A; Boux L; Chong P
Mol Immunol; 1991 Mar; 28(3):251-5. PubMed ID: 2017196
[TBL] [Abstract][Full Text] [Related]
6. Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
Olander RM; Muotiala A; Karvonen M; Kuronen T; Runeberg-Nyman K
Microb Pathog; 1990 Jan; 8(1):37-45. PubMed ID: 2159104
[TBL] [Abstract][Full Text] [Related]
7. Interaction of Bordetella pertussis virulence components with neutrophils: effect on chemiluminescence induced by a chemotactic peptide and by intact bacteria.
Craig FF; Lackie JM; Parton R; Freer JH
J Gen Microbiol; 1988 Aug; 134(8):2201-11. PubMed ID: 2908118
[TBL] [Abstract][Full Text] [Related]
8. Does whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3.
Ramkissoon A; Coovadia HM; Loening WE; Ndlovana M
S Afr Med J; 1991 Jun; 79(11):645-9. PubMed ID: 1675492
[TBL] [Abstract][Full Text] [Related]
9. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
Thomas MG; Ashworth LA; Miller E; Lambert HP
J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
[TBL] [Abstract][Full Text] [Related]
10. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
11. [Inactivation and toxoiding of biologically-active components of Bordetella pertussis by tea catechins].
Watanabe M; Endoh M; Takeo T
Yakugaku Zasshi; 1998 Sep; 118(9):415-22. PubMed ID: 9779002
[TBL] [Abstract][Full Text] [Related]
12. Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure.
Christodoulides M; Sidey FM; Parton R; Stewart-Tull DE
Vaccine; 1987 Sep; 5(3):199-207. PubMed ID: 2890244
[TBL] [Abstract][Full Text] [Related]
13. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.
Alonso S; Pethe K; Mielcarek N; Raze D; Locht C
Infect Immun; 2001 Oct; 69(10):6038-43. PubMed ID: 11553541
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of active pertussis toxin may aid a pertussis vaccine to pass the mouse body weight gain test.
Horiuchi Y; Takahashi M; Asada S; Ishida S
Biologicals; 1994 Sep; 22(3):243-8. PubMed ID: 7811458
[TBL] [Abstract][Full Text] [Related]
15. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
16. Effect of hyperreactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice.
Sidey FM; Furman BL; Wardlaw AC
Vaccine; 1989 Jun; 7(3):237-41. PubMed ID: 2781857
[TBL] [Abstract][Full Text] [Related]
17. Chick embryo, a model to study the lethal activity of pertussis toxin, infectivity of Bordetella pertussis, and their neutralization by immune sera.
Calver GA; Burton WW; Gardell CY
Can J Microbiol; 1993 Aug; 39(8):759-66. PubMed ID: 8106134
[TBL] [Abstract][Full Text] [Related]
18. Bacterial growth and virulence factors production by different Bordetella pertussis strains.
Letowska I; Chodorowska M; Kaczurba E; Kuklińska D; Tyski S
Acta Microbiol Pol; 1997; 46(1):45-55. PubMed ID: 9271847
[TBL] [Abstract][Full Text] [Related]
19. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
20. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
